earnings
confidence high
sentiment positive
materiality 0.80
BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria
BIOCRYST PHARMACEUTICALS INC
2025-Q3 EPS reported
$0.08
revenue$468,282,000
- ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).
- Net income $12.9M ($0.06) vs net loss $14.0M ($0.07 loss) prior year; non-GAAP net income $35.6M ($0.17).
- FY 2025 ORLADEYO rev guidance raised to $590-600M; non-GAAP op expense lowered to $430-440M; on track for positive cash flow.
- Sale of European ORLADEYO business closed; proceeds used to retire remaining $198.7M Pharmakon term debt; pro forma cash $294M.
- Definitive agreement to acquire Astria Therapeutics (navenibart Phase 3 HAE); expected close Q1 2026; Ron Dullinger named CCO effective Jan 1, 2026.